Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax
Charles “Charlie” Fuchs is joining Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit as SVP and global head of product development for oncology and hematology. Fuchs, who will start March 1 and be based in South San Francisco, is director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital.
Brandi Roberts left Lineage Cell Therapeutics Inc. (NYSE-A:LCTX) to join Longboard Pharmaceuticals Inc. as CFO. Lineage CEO Brian Culley will serve as interim CFO until the position is filled. Longboard spun out of Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in the fall to develop a trio of neuroscience programs. It raised $56 million from a syndicate led by Farallon Capital Management that brings deep-pocketed investors into the fold for a company whose road map includes a potential IPO...